M
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ: MLTX (MoonLake Immunotherapeutics)
Last update: 4 hours ago17.96
-1.45 (-7.47%)
| Previous Close | 19.41 |
| Open | 19.50 |
| Volume | 1,228,888 |
| Avg. Volume (3M) | 1,390,901 |
| Market Cap | 1,288,232,576 |
| Price / Book | 3.83 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Diluted EPS (TTM) | -2.30 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 21.11 |
| Operating Cash Flow (TTM) | -139.78 M |
| Levered Free Cash Flow (TTM) | -102.40 M |
| Return on Assets (TTM) | -19.85% |
| Return on Equity (TTM) | -30.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | MoonLake Immunotherapeutics | Bullish | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.80 |
|
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 15.34% |
| % Held by Institutions | 96.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (Clear Street, 289.76%) | Buy |
| Median | 30.00 (67.04%) | |
| Low | 10.00 (Goldman Sachs, -44.32%) | Sell |
| Average | 31.86 (77.39%) | |
| Total | 5 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 17.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Clear Street | 11 Mar 2026 | 70.00 (289.76%) | Buy | 17.84 |
| HC Wainwright & Co. | 02 Mar 2026 | 40.00 (122.72%) | Buy | 17.68 |
| 03 Feb 2026 | 32.00 (78.17%) | Buy | 15.37 | |
| RBC Capital | 02 Mar 2026 | 13.00 (-27.62%) | Hold | 17.68 |
| 20 Feb 2026 | 12.00 (-33.18%) | Hold | 18.77 | |
| Needham | 26 Feb 2026 | 25.00 (39.20%) | Buy | 17.68 |
| 23 Feb 2026 | 25.00 (39.20%) | Buy | 18.68 | |
| Oppenheimer | 24 Feb 2026 | 35.00 (94.88%) | Buy | 18.20 |
| BTIG | 23 Feb 2026 | 30.00 (67.04%) | Buy | 18.68 |
| 09 Feb 2026 | 24.00 (33.63%) | Buy | 15.75 | |
| Goldman Sachs | 15 Jan 2026 | 10.00 (-44.32%) | Sell | 16.35 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | - | 18.64 | -3,750,000 | -69,900,000 |
| Aggregate Net Quantity | -3,750,000 | |||
| Aggregate Net Value ($) | -69,900,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 18.64 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BVF PARTNERS L P/IL | Director | 31 Mar 2026 | Sell (-) | 3,750,000 | 18.64 | 69,900,000 |
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day |
| 02 Feb 2026 | Announcement | MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |